Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Selective factor Xa inhibitor assessed in experimental model of tumor-induced DIC

Jan. 13, 2000

Phase III data reported for rhATIII

Jan. 12, 2000

New thrombin inhibitors presented by Merck & Co. research group

Jan. 6, 2000

Condensed heterocycles and ester prodrugs as potent antiplatelet, antithrombotic agents

Jan. 5, 2000

Merck describes thrombin-specific anticoagulants

Jan. 3, 2000

New approach to inhibiting thrombin-induced neuronal cell death

Dec. 29, 1999

Update on preclinical and clinical testing of R.W. Johnson's fibrinogen antagonist

Dec. 27, 1999

Recently issued patent covers Berlex's new anticoagulants

Dec. 23, 1999

Selective, orally active factor Xa inhibitors designed by JT scientists

Dec. 22, 1999

Meiji Seika presents heterocyclic inhibitors of platelet aggregation

Dec. 22, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...